

dronabinol oral solution (SYNDROS)

Diagnosis Considered for Coverage:

- Anorexia associated with weight loss in patients with AIDS
- Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments

Coverage Criteria:

For diagnosis listed above:

- Intolerance or contraindication to dronabinol capsule not expected with the dronabinol solution, **and**
- Dose does not FDA label maximum:
 - Nausea and vomiting: 12.6 mg/m² per dose, for 4 to 6 doses per day.
 - Anorexia: 16.8 mg per day in divided doses.

Coverage Duration:

Nausea and vomiting: duration of chemotherapy

Anorexia: one year

Effective Date: 11/30/2022